TIMP2 and ovarian carcinoma: Although paclitaxel enhanced TIMP-1 expression on parental OVCAR4 cells, Momelotinib had no effect on its expression, strongly suggesting that TIMP-2 mediated chemotherapy-induced STAT3 activation is essential for chemoresistant and CSC phenotypes in ovarian cancer.